Market brief
European Ophthalmology & Dermatology Therapeutics 2026: LEO Pharma, Arctic Bioscience, Aranda, BioResearch Pharma
European ophthalmology and dermatology therapeutics in 2026 span 10 directly-attributed directory-surfaced operators (plus 4 cross-referenced from adjacent briefs) across three overlapping tracks: large-cap commercial dermatology pharma (LEO Pharma, Bayer Turku — adjacent), clinical-stage dermatology + alopecia + psoriasis (Arctic Bioscience, Aranda Pharma, BioResearch Pharma), and ophthalmic + regenerative-skin + wound-care (Pharmidea ophthalmic, Aurealis Therapeutics for diabetic foot ulcer, plus tissue-engineering operators Verigraft, ClexBio, Vital3D, Gelatex, Cellbox Labs, Printymed). Denmark concentrates the directory’s commercial dermatology anchor through LEO Pharma (Ballerup). Norway adds marine-lipid psoriasis (Arctic Bioscience). Finland adds topical androgen-receptor dermatology (Aranda Pharma) and live-biotherapeutic for diabetic foot ulcer (Aurealis Therapeutics — covered in microbiome brief). Poland adds drug-repositioning dermatology (BioResearch Pharma). The Nordic + Baltic + Polish tissue-engineering + regenerative-medicine layer (Verigraft, ClexBio, Vital3D, Gelatex, Cellbox Labs, Printymed) supplies the underlying biomaterial + scaffold + organ-on-chip infrastructure for skin and ophthalmic translational work. Adjacent operators in cell + gene therapy ATMPs for ophthalmic indications and rare-disease orphan dermatology are covered in the Cell & Gene Therapy 2026 and Rare Disease 2026 briefs.
Summary
Key findings
LEO Pharma (Ballerup, Denmark) is the directory-surfaced large-cap commercial dermatology anchor with global specialty-pharma operations across psoriasis (including Adtralza / tralokinumab for atopic dermatitis, EU + US approved 2021), eczema, actinic keratosis, and chronic skin disease portfolios.
Arctic Bioscience (Ørsta, Norway) develops marine-lipid therapeutics including HRO350 (herring-roe phospholipid extract) at Phase IIb (HeROPA trial) for mild-to-moderate psoriasis — a directory-surfaced Norwegian dermatology clinical-stage programme.
Aranda Pharma (Kuopio, Finland) develops non-steroidal androgen-receptor inhibitors at preclinical stage for topical dermatology including androgenetic alopecia and acne; BioResearch Pharma (Warsaw, Poland) runs drug-repositioning programmes in androgenetic alopecia and psoriasis.
European tissue engineering + regenerative skin + biomaterial scaffold operators include Verigraft (Gothenburg, vascular grafts + ATMP regenerative), ClexBio (Oslo, CLEX hydrogel scaffold), Vital3D (Vilnius, 3D bioprinting + vascularised tissue + personalised medicine), Gelatex (Tallinn, nanofibrous tissue-engineering materials), Cellbox Labs (Adazi, organ-on-a-chip systems), Printymed (Jelgava District, biomimetic spider silk + biomaterial scaffolds + organ-on-a-chip membranes).
Numbers
Quick numbers
Analysis
LEO Pharma and the Danish dermatology anchor
Denmark concentrates the directory’s commercial dermatology pharma anchor through LEO Pharma (Ballerup). LEO Pharma runs commercial-stage dermatology + global specialty-pharma operations across psoriasis (Enstilar calcipotriene/betamethasone foam, Daivobet topical, Adtralza / Adbry tralokinumab IL-13 antibody for moderate-to-severe atopic dermatitis approved by EMA + FDA in 2021), eczema and atopic dermatitis (Adtralza / Adbry, plus delgocitinib topical pan-JAK inhibitor for chronic hand eczema approved by EMA September 2024 and by FDA July 2025 as Anzupgo), and actinic keratosis + chronic-wound + thrombosis adjacencies (innohep tinzaparin LMWH). LEO Pharma’s spinout LEO Foundation Center for Cutaneous Drug Delivery and the broader LEO Pharma R&D pipeline cover next-generation dermatology biologics + small molecules.
Analysis
Norwegian, Finnish, and Polish clinical-stage dermatology + alopecia
Beyond the Danish anchor, the directory surfaces three clinical-stage dermatology operators. Arctic Bioscience (Ørsta, Norway) develops marine-lipid therapeutics with HRO350 (herring-roe phospholipid extract) at Phase IIb (HeROPA trial) for mild-to-moderate psoriasis — a directory-surfaced Norwegian dermatology programme. Aranda Pharma (Kuopio, Finland) develops non-steroidal androgen-receptor inhibitors at preclinical stage for topical dermatology indications including androgenetic alopecia + acne. BioResearch Pharma (Warsaw, Poland) runs early-stage (pre-Phase I) drug-repositioning programmes in androgenetic alopecia + psoriasis using approved-molecule reformulation. Together these three operators cover the directory-surfaced clinical-stage European dermatology programmes across psoriasis + alopecia + acne.
Analysis
Ophthalmic and wound-care therapeutics
European ophthalmic + wound-care therapeutics span directory operators including Pharmidea (Olaine, Latvia) for sterile pharmaceutical products including injectable + ophthalmic + hospital medicines (covered in the European Sterile Fill-Finish CDMO 2026 brief). Aurealis Therapeutics (Kuopio, Finland) develops AUP1602-C engineered live-biotherapeutic for diabetic foot ulcer — a wound-care + chronic-skin-condition adjacency covered in the European Microbiome & Live Biotherapeutics 2026 brief. AlgiPharma (Sandvika, Norway) develops alginate-oligomer therapeutics for cystic-fibrosis biofilm + chronic-wound + antimicrobial-resistance applications — covered in the European Anti-Infectives & AMR 2026 brief. For dedicated retinal + corneal + glaucoma therapeutic operators, the directory surfaces limited European clinical-stage activity in 2026 — sponsors should evaluate adjacencies and the rare-disease orphan-ophthalmic operators covered in the European Rare Disease & Orphan Therapeutics 2026 brief.
Analysis
Tissue engineering, regenerative skin, and biomaterial scaffolds
European tissue engineering + regenerative-skin + biomaterial-scaffold operators supply the underlying infrastructure for dermatology + ophthalmic translational work. Verigraft (Gothenburg, Sweden) develops personalised vascular grafts + tissue-engineered ATMPs + regenerative-medicine clinical development. ClexBio (Oslo, Norway) develops the CLEX hydrogel scaffold technology for tissue engineering + regenerative-medicine applications. Vital3D (Vilnius, Lithuania) develops 3D bioprinting + vascularised tissue models + personalised-medicine applications including skin and tissue model platforms. Gelatex (Tallinn, Estonia) provides nanofibrous tissue-engineering materials + 3D cell culture + contract material development for regenerative + cosmetic + research markets. Cellbox Labs (Ādaži, Latvia) provides organ-on-a-chip systems + vascularised tissue models + automated cell culture + in-vitro applications. Printymed (Jelgava District, Latvia) develops biomimetic spider silk + biomaterial scaffolds + organ-on-a-chip membranes + regenerative applications. TissUse (Berlin) and InSphero (Schlieren) add organ-on-chip + 3D cell-culture infrastructure relevant to dermatology + ophthalmic in-vitro modelling — covered in the European AI Drug Discovery & Computational Biology 2026 brief.
Analysis
Adjacent: rare ophthalmology, ATMP gene therapy, and dermatology diagnostics
Several adjacent ophthalmology + dermatology modalities sit alongside this brief. Rare ophthalmology + orphan-designated ophthalmic assets are covered in the European Rare Disease & Orphan Therapeutics 2026 brief — including operators with rare-disease orphan ophthalmic adjacencies. Cell + gene therapy for inherited retinal disease (e.g. Luxturna-class ATMPs) is covered in the European Cell & Gene Therapy Europe 2026 brief through ATMP CDMO operators (Kuopio Center for Gene and Cell Therapy, Antion Biosciences, Fuse Vectors, AGC Biologics). Visiopharm (Hørsholm, Denmark) develops digital-pathology + tissue-image-analysis software with applications including dermatopathology — covered in the European AI Drug Discovery & Computational Biology 2026 brief. CeGaT (Tübingen, Germany) provides clinical NGS + whole-exome + whole-genome sequencing including dermatological + ophthalmological genetic diagnostics — covered in the European Genomics & Sequencing 2026 brief.
Analysis
How to pick a European ophthalmology / dermatology partner in 2026
Match the decision to the indication. Commercial dermatology partnership / licensing (psoriasis + atopic dermatitis + chronic hand eczema): LEO Pharma (Ballerup, Adtralza tralokinumab, Anzupgo delgocitinib). Marine-lipid clinical-stage psoriasis: Arctic Bioscience (Ørsta). Topical androgen-receptor for androgenetic alopecia + acne: Aranda Pharma (Kuopio). Drug-repositioning alopecia + psoriasis: BioResearch Pharma (Warsaw). Sterile ophthalmic injectables manufacturing: Pharmidea (Olaine). Engineered live-biotherapeutic for diabetic foot ulcer: Aurealis Therapeutics (Kuopio). Cystic-fibrosis + chronic-wound biofilm-disruption alginate: AlgiPharma (Sandvika). Personalised vascular grafts + regenerative ATMP: Verigraft (Gothenburg). CLEX hydrogel scaffold tissue engineering: ClexBio (Oslo). 3D bioprinting + vascularised tissue models: Vital3D (Vilnius). Nanofibrous tissue-engineering materials: Gelatex (Tallinn). Organ-on-a-chip + vascularised tissue models: Cellbox Labs (Adazi). Biomimetic spider-silk biomaterial scaffolds: Printymed (Jelgava District). Dermatopathology + ophthalmic image analysis: Visiopharm (Hørsholm). Inherited-retinal-disease ATMP CDMO: Kuopio Center for Gene and Cell Therapy. The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.
What to watch
What to watch next
LEO Pharma Anzupgo delgocitinib commercial rollout + new dermatology biologics pipeline
Arctic Bioscience HRO350 Phase IIb psoriasis readouts
Aranda Pharma topical androgen-receptor clinical milestones
BioResearch Pharma alopecia + psoriasis drug-repositioning readouts
Aurealis AUP1602-C diabetic foot ulcer clinical milestones
Verigraft + ClexBio + Vital3D + Gelatex tissue-engineering commercial milestones
Cellbox Labs + Printymed Baltic biomaterial + organ-on-a-chip licensing milestones
FAQ
Frequently asked questions
Who is the main European commercial dermatology pharma in 2026?
LEO Pharma (Ballerup, Denmark) is the directory-surfaced commercial dermatology + specialty-pharma anchor with global operations across psoriasis (Daivobet, Enstilar), atopic dermatitis (Adtralza / Adbry tralokinumab IL-13 antibody approved EMA + FDA 2021), chronic hand eczema (Anzupgo delgocitinib pan-JAK inhibitor approved EMA September 2024; FDA approved July 2025), actinic keratosis, and chronic-wound + thrombosis adjacencies. For European commercial dermatology partnership or licensing, LEO Pharma is the directory’s primary Danish operator.
Where do European clinical-stage dermatology + alopecia operators sit?
Three directory operators run clinical-stage dermatology programmes. Arctic Bioscience (Ørsta, Norway) develops HRO350 (herring-roe phospholipid extract) at Phase IIb (HeROPA trial) for mild-to-moderate psoriasis. Aranda Pharma (Kuopio, Finland) develops non-steroidal androgen-receptor inhibitors at preclinical stage for topical dermatology including androgenetic alopecia + acne. BioResearch Pharma (Warsaw, Poland) runs drug-repositioning programmes in androgenetic alopecia + psoriasis.
How does European tissue-engineering + regenerative skin work?
Six directory operators across the Nordic + Baltic + Polish tissue-engineering layer. Verigraft (Gothenburg) develops personalised vascular grafts + tissue-engineered ATMPs. ClexBio (Oslo) develops the CLEX hydrogel scaffold. Vital3D (Vilnius) develops 3D bioprinting + vascularised tissue + personalised-medicine applications. Gelatex (Tallinn) provides nanofibrous tissue-engineering materials. Cellbox Labs (Adazi, Latvia) provides organ-on-a-chip systems + vascularised tissue models. Printymed (Jelgava District, Latvia) develops biomimetic spider silk + biomaterial scaffolds.
Where do ophthalmic and wound-care therapeutics fit?
Pharmidea (Olaine, Latvia) provides sterile ophthalmic + injectable + hospital medicines manufacturing. Aurealis Therapeutics (Kuopio) develops AUP1602-C engineered live-biotherapeutic for diabetic foot ulcer. AlgiPharma (Sandvika) develops alginate-oligomer therapeutics for chronic-wound biofilm. For dedicated retinal + corneal + glaucoma therapeutic operators, the directory surfaces limited European clinical-stage activity in 2026 — sponsors should evaluate the rare-disease orphan-ophthalmic operators covered in the European Rare Disease & Orphan Therapeutics 2026 brief and the inherited-retinal-disease ATMP layer covered in the European Cell & Gene Therapy Europe 2026 brief.
How do dermatology diagnostics and digital pathology connect?
Visiopharm (Hørsholm) develops digital-pathology + tissue-image-analysis software with applications including dermatopathology — covered in the European AI Drug Discovery & Computational Biology 2026 brief. CeGaT (Tübingen) provides clinical NGS + whole-exome + whole-genome sequencing including dermatological + ophthalmological genetic diagnostics — covered in the European Genomics & Sequencing 2026 brief. Hummingbird Diagnostics (Heidelberg) provides miRNA-based liquid biopsy with neurology + oncology applications adjacent to inflammatory dermatology biomarker discovery.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for every dermatology + ophthalmology + tissue-engineering operator, official company disclosures, EMA + FDA approval records (Adtralza / Adbry tralokinumab, Anzupgo delgocitinib), and editorial cross-reference against the European Rare Disease & Orphan Therapeutics 2026, European Cell & Gene Therapy Europe 2026, European Microbiome & Live Biotherapeutics 2026, European Anti-Infectives & AMR 2026, European Sterile Fill-Finish CDMO 2026, European AI Drug Discovery & Computational Biology 2026, and European Genomics & Sequencing 2026 briefs. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible European ophthalmology + dermatology + regenerative-skin activity in 2026. Product names, regulatory approvals, brand names, and partnership details reflect publicly disclosed information as of directory review — verify directly with each operator before engagement. The directory currently surfaces limited European clinical-stage retinal + corneal + glaucoma therapeutic activity, which may underrepresent the broader European ophthalmology landscape; sponsors with retinal therapeutic interest should consult dedicated ophthalmic indices alongside this brief.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.